Table 3.

Potential risk factors for TA-TMA.

Inherent/non-modifiable	Transplant-associated	Post-transplant events
Female sex	HLA-mismatched donor	CNI ± Sirolimus
Gene variants	Minor ABO mismatch	Infection (Bacteremia or IFI)
African-American race	Use of PBSC	Infection (DS-DNA Virus, e.g., CMV, HHV-6, BK)
Severe aplastic anemia	Lack of ATG in conditioning regimen	Acute GVHD
CMV seropositive recipient	Myeloablative conditioning	Autoantibody formation (Factor H, others)
Prior HCT	Slow metabolism of conditioning agents?

HLA, human leukocyte antigen; CNI, calcineurin inhibitor; ABO, blood type antigens; IFI, invasive fungal infection; PBSC, peripheral blood stem cells; GVHD, graft-vs. -host disease; CMV, cytomegalovirus; HHV-6, human herpes virus-6; ATG, anti-thymocyte globulin; HCT, hematopoietic cell transplant.